RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Laboratorios Farmaceuticos ROVI Stock

Laboratorios Farmaceuticos ROVI P/E 2024

Laboratorios Farmaceuticos ROVI P/E

28.38

Ticker

ROVI.MC

ISIN

ES0157261019

WKN

A0M0GQ

As of Dec 21, 2024, Laboratorios Farmaceuticos ROVI's P/E ratio was 28.38, a 120% change from the 12.9 P/E ratio recorded in the previous year.

The Laboratorios Farmaceuticos ROVI P/E history

Laboratorios Farmaceuticos ROVI Aktienanalyse

What does Laboratorios Farmaceuticos ROVI do?

Laboratorios Farmaceuticos ROVI SA is a Spanish pharmaceutical company that was founded in 1946 by Salvador and Ignacio Ruiz-Salmones. The company is headquartered in Madrid and employs over 1,000 employees. ROVI manufactures a variety of pharmaceutical products and offers services in various areas. The company specializes in the development and manufacturing of specialty preparations in the fields of oncology, hematology, endocrinology, and gastroenterology. The company operates in three business areas: specialty pharmaceuticals, contrast agents, and active ingredients for the industry. The specialty pharmaceuticals business area includes medications for various applications, such as the treatment of cancer, blood disorders, endocrine disorders, gastroenterological disorders, and central nervous system disorders. The contrast agents division produces products for radiology and diagnostics. The products are used in various medical fields, from cardiology to gastroenterology. In the active ingredients for the industry business area, ROVI manufactures active ingredients for other pharmaceutical companies. ROVI specializes in the production of specialty products and relies on collaborations with other companies. The company has strategic partnerships with many companies such as GlaxoSmithKline, Pfizer, Sanofi-Aventis, and Zeltia. This also includes some research collaborations to develop and market products together. The company is also dedicated to the development of biosimilars, which allow for the offering of biologic drugs at a lower price. Biosimilars are copies of biopharmaceuticals that are usually very expensive due to the complex manufacturing process and high development costs. ROVI is also a major producer of vaccines that are distributed worldwide. ROVI has followed a solid growth trajectory in recent years. The company has been able to consistently increase its revenue and profit and is now a major player in the pharmaceutical industry. The company also operates a strong research and development department that constantly develops new products and technologies to improve patient care. In summary, Laboratorios Farmaceuticos ROVI SA is a leading pharmaceutical company specializing in the manufacturing of specialty products. With its subsidiaries in Europe and the USA, ROVI has an international presence and has made a name for itself through its expertise in the development and manufacturing of innovative pharmaceutical products. Laboratorios Farmaceuticos ROVI ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/E Details

Deciphering Laboratorios Farmaceuticos ROVI's P/E Ratio

The Price to Earnings (P/E) Ratio of Laboratorios Farmaceuticos ROVI is a vital metric that investors and analysts use to determine the company’s market value relative to its earnings. It is calculated by dividing the current stock price by the earnings per share (EPS). A higher P/E ratio could suggest that investors are expecting higher future growth, while a lower ratio may indicate a potentially undervalued company or lower growth expectations.

Year-to-Year Comparison

Assessing Laboratorios Farmaceuticos ROVI's P/E ratio on a yearly basis provides insights into the valuation trends and investor sentiment. An increasing P/E ratio over the years signifies growing investor confidence and expectations for future earnings growth, while a decreasing ratio may reflect concerns over the company's profitability or growth prospects.

Impact on Investments

The P/E ratio of Laboratorios Farmaceuticos ROVI is a key consideration for investors aiming to balance risk and reward. A comprehensive analysis of this ratio, in conjunction with other financial indicators, aids investors in making informed decisions regarding buying, holding, or selling the company’s stocks.

Interpreting P/E Ratio Fluctuations

Fluctuations in Laboratorios Farmaceuticos ROVI’s P/E ratio can be attributed to various factors including changes in earnings, stock price movements, and shifts in investor expectations. Understanding the underlying reasons for these fluctuations is essential for predicting future stock performance and assessing the company's intrinsic value.

Frequently Asked Questions about Laboratorios Farmaceuticos ROVI stock

What is the price-to-earnings ratio of Laboratorios Farmaceuticos ROVI?

The price-earnings ratio of Laboratorios Farmaceuticos ROVI is currently 28.38.

How has the price-earnings ratio of Laboratorios Farmaceuticos ROVI changed compared to last year?

The price-to-earnings ratio of Laboratorios Farmaceuticos ROVI has increased by 120% increased compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Laboratorios Farmaceuticos ROVI high compared to other companies?

Yes, the price-to-earnings ratio of Laboratorios Farmaceuticos ROVI is high compared to other companies.

How does an increase in the price-earnings ratio of Laboratorios Farmaceuticos ROVI affect the company?

An increase in the price-earnings ratio of Laboratorios Farmaceuticos ROVI would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Laboratorios Farmaceuticos ROVI affect the company?

A decrease in the price-earnings ratio of Laboratorios Farmaceuticos ROVI would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Laboratorios Farmaceuticos ROVI?

Some factors that influence the price-earnings ratio of Laboratorios Farmaceuticos ROVI are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Laboratorios Farmaceuticos ROVI pay?

Over the past 12 months, Laboratorios Farmaceuticos ROVI paid a dividend of 1.29 EUR . This corresponds to a dividend yield of about 2.11 %. For the coming 12 months, Laboratorios Farmaceuticos ROVI is expected to pay a dividend of 1.69 EUR.

What is the dividend yield of Laboratorios Farmaceuticos ROVI?

The current dividend yield of Laboratorios Farmaceuticos ROVI is 2.11 %.

When does Laboratorios Farmaceuticos ROVI pay dividends?

Laboratorios Farmaceuticos ROVI pays a quarterly dividend. This is distributed in the months of August, August, August, August.

How secure is the dividend of Laboratorios Farmaceuticos ROVI?

Laboratorios Farmaceuticos ROVI paid dividends every year for the past 21 years.

What is the dividend of Laboratorios Farmaceuticos ROVI?

For the upcoming 12 months, dividends amounting to 1.69 EUR are expected. This corresponds to a dividend yield of 2.75 %.

In which sector is Laboratorios Farmaceuticos ROVI located?

Laboratorios Farmaceuticos ROVI is assigned to the 'Health' sector.

Wann musste ich die Aktien von Laboratorios Farmaceuticos ROVI kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Laboratorios Farmaceuticos ROVI from 7/10/2024 amounting to 1.104 EUR, you needed to have the stock in your portfolio before the ex-date on 7/8/2024.

When did Laboratorios Farmaceuticos ROVI pay the last dividend?

The last dividend was paid out on 7/10/2024.

What was the dividend of Laboratorios Farmaceuticos ROVI in the year 2023?

In the year 2023, Laboratorios Farmaceuticos ROVI distributed 0.956 EUR as dividends.

In which currency does Laboratorios Farmaceuticos ROVI pay out the dividend?

The dividends of Laboratorios Farmaceuticos ROVI are distributed in EUR.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Laboratorios Farmaceuticos ROVI

Our stock analysis for Laboratorios Farmaceuticos ROVI Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Laboratorios Farmaceuticos ROVI Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.